DanCann Pharma A/S appoints Jens Markussen as Head of Production

Report this content

COPENHAGEN, Denmark, 9 March 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) is pleased to announce the employment of Jens Markussen. Jens Markussen has been appointed as Head of Production at DanCann Pharma A/S.

Jens Markussen joins the DanCann Pharma production team as the company’s Head of Production. Jens Markussen will oversee all production and post-harvest activities of the BIOTECH PHARM1. This includes standardization of operations, compliance, applications, and approvals related to products produced at DanCann Pharma’s BIOTECH PHARM1.

Jens Markussen has already a proven track record within the medical cannabis industry as he is former Head of Production at Spectrum Therapeutics Denmark A/S, part of the Canopy Growth Corp. (NASDAQ: CGC) group. During his time at Spectrum Therapeutics Denmark, Jens has overseen the construction and approval of a 2,500 m2 GMP-facility for harvesting, drying, and packaging of dried cannabis. Before his time at Spectrum Therapeutics Denmark, Jens worked as Production Manager at Fertin Pharma A/S. In addition, Jens has proven track record in process and LEAN optimization within the pharma- and medical cannabis industry.

Jens explains: ”From my very first meeting with the DanCann Pharma team, I was determined to join and be part of the company. My previous proven track-record, expertise and knowledge with Medical Cannabis production will aid DanCann Pharma towards the important, forthcoming milestone - the GMP approval of BIOTECH PHARM1 later this year. I am very excited to work with the DanCann Pharma team who share a such strong passion for improving quality of life for patients with challenges. I look forward to the exciting months to come.”

Morten Martinsen, COO at DanCann Pharma elaborates: “Jens' know-how and experience with Medical cannabis under Danish and European regulations are exceptional and one-of-a-kind in this novel industry - these will aid DanCann Pharma’s production activities- and ease application and approval processes with the Danish Medical Agency.

We are very excited about the appointment of Jens Markussen as Head of Production. It is a significant and important step for DanCann pharma and towards the forthcoming GMP-approval of BIOTECH PHARM1.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Website: www.dancann.com


Documents & Links